Marie-Laure Nicolau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marie-Laure Nicolau has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Christian Récher
CHU de Toulouse, Toulouse, France
34 shared publications - François Vergez
CHU Toulouse, Laboratoire Hématologie Toulouse France
34 shared publications - Véronique Mansat-De Mas
Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Laboratoire D'hématologie Toulouse France
34 shared publications - Ambrine Sahal
Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France
25 shared publications - Audrey Carrière
STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France
25 shared publications - Camille Bergoglio
Team MetaDiab, Inserm UMR1297, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
25 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S6 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Supplemental Table 1. Characteristics of AML patients. Supplemental Table 2. Flow cytometry antibodies. Supplemental Table 3. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients. Supplemental Table 4. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients. Supplemental Table 5. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients including the association of bulk and LSC MRD parameters. Supplemental Table 6. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients including the association of bulk and LSC MRD parameters.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S6 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Supplemental Table 1. Characteristics of AML patients. Supplemental Table 2. Flow cytometry antibodies. Supplemental Table 3. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients. Supplemental Table 4. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients. Supplemental Table 5. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients including the association of bulk and LSC MRD parameters. Supplemental Table 6. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients including the association of bulk and LSC MRD parameters.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Supplemental figure 1. Flow chart for sample availability of patients included in our study and their outcome. Supplemental figure 2. Supplemental figure 3. Size of LSC nodes in CD34+CD38- subpopulation in AML-CD34+ and AMLCD34- populations. Mann-Whitney test. Supplemental figure 4. LSC phenotypic profiles according to MRD status. Normalized MFI of CD34, CD38, CD45RA, CD135 and CD133 in LSC nodes used to measure LSC MRD. Mann-Whitney tests. Supplemental figure 5. Landmark analysis at 6 months of the impact of HSCT according to MRD status. Supplemental figure 6. Evaluation of immunophenotypic markers in chemoresistant and chemosensitive AML patients at diagnosis. Supplemental figure 7. Evaluation of LSC phenotypic markers in clinically relevant AML patients in relation to Figure 4.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Supplemental figure 1. Flow chart for sample availability of patients included in our study and their outcome. Supplemental figure 2. Supplemental figure 3. Size of LSC nodes in CD34+CD38- subpopulation in AML-CD34+ and AMLCD34- populations. Mann-Whitney test. Supplemental figure 4. LSC phenotypic profiles according to MRD status. Normalized MFI of CD34, CD38, CD45RA, CD135 and CD133 in LSC nodes used to measure LSC MRD. Mann-Whitney tests. Supplemental figure 5. Landmark analysis at 6 months of the impact of HSCT according to MRD status. Supplemental figure 6. Evaluation of immunophenotypic markers in chemoresistant and chemosensitive AML patients at diagnosis. Supplemental figure 7. Evaluation of LSC phenotypic markers in clinically relevant AML patients in relation to Figure 4.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
Human antibodies for flow cytometry analyses (TUH cohort)
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
Human antibodies for flow cytometry analyses (TUH cohort)
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
Multivariate analysis of the TUH cohort
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
Multivariate analysis of the TUH cohort
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia